{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:14:50Z","timestamp":1783440890363,"version":"3.54.6"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"University of Bergen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metabolomics"],"DOI":"10.1007\/s11306-026-02421-9","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T12:42:57Z","timestamp":1776429777000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolomics profiling of acute myelogenous leukemia patients to identify systemic differences associated with in vitro sensitivity to SYK inhibitors"],"prefix":"10.1007","volume":"22","author":[{"given":"Marte Karen","family":"Bratt\u00e5s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberley Joanne","family":"Hatfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Paulsen Rye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e5kon","family":"Reikvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"1","key":"2421_CR1","doi-asserted-by":"publisher","first-page":"5973","DOI":"10.1182\/blood-2023-178804","volume":"142","author":"M Arnan","year":"2023","unstructured":"Arnan, M., Patel, A. A., Esteve, J., Morris, L., Schiller, G. J., Swords, R. T., Alonso-Dominguez, J. M., Michaelis, L. C., Daver, N., Carvajal, L. A., Bray, G., Olek, E., Cutler, R. E., DiMartino, J. F., & Stein, E. M. (2023). KB-Lanra 1001: A phase 1b\/2 study of safety, PK, PD, and preliminary efficacy of the selective SYK inhibitor lanraplenib in combination with the FLT3 inhibitor gilteritinib in FLT3-mutated R\/R AML. Blood, 142(1), 5973\u20135973. https:\/\/doi.org\/10.1182\/blood-2023-178804","journal-title":"Blood"},{"issue":"1","key":"2421_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-48970-0","volume":"13","author":"L Bolkun","year":"2023","unstructured":"Bolkun, L., Pienkowski, T., Sieminska, J., Godzien, J., Pietrowska, K., K\u0142oczko, J., Wierzbowska, A., Moniuszko, M., Ratajczak, M., Kretowski, A., & Ciborowski, M. (2023). Metabolomic profile of acute myeloid leukaemia parallels of prognosis and response to therapy. Scientific Reports, 13(1), Article 21809. https:\/\/doi.org\/10.1038\/s41598-023-48970-0","journal-title":"Scientific Reports"},{"issue":"28","key":"2421_CR3","doi-asserted-by":"publisher","first-page":"25575","DOI":"10.18632\/oncotarget.4669","volume":"6","author":"K Boros","year":"2015","unstructured":"Boros, K., Puissant, A., Back, M., Alexe, G., Bassil, C. F., Sinha, P., Tholouli, E., Stegmaier, K., Byers, R. J., & Rodig, S. J. (2015). Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia. Oncotarget, 6(28), 25575\u201325587. https:\/\/doi.org\/10.18632\/oncotarget.4669","journal-title":"Oncotarget"},{"issue":"2","key":"2421_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70058","volume":"43","author":"MK Bratt\u00e5s","year":"2025","unstructured":"Bratt\u00e5s, M. K., G\u00f6rtler, F., Johansen, S., Rye, K. P., Hatfield, K. J., & Reikvam, H. (2025). Gene expression profiling in acute myeloid leukemia patient subgroups with high and low sensitivity toward SYK inhibitors. Hematological Oncology, 43(2), Article e70058. https:\/\/doi.org\/10.1002\/hon.70058","journal-title":"Hematological Oncology"},{"issue":"23","key":"2421_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314706","volume":"23","author":"MK Bratt\u00e5s","year":"2022","unstructured":"Bratt\u00e5s, M. K., Hemsing, A. L., Rye, K. P., Hatfield, K. J., & Reikvam, H. (2022). Heterogeneity of patient-derived acute myeloid leukemia cells subjected to SYK in vitro inhibition. International Journal of Molecular Sciences, 23(23), Article 14706. https:\/\/doi.org\/10.3390\/ijms232314706","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"2421_CR6","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1182\/blood-2021-145773","volume":"138","author":"JC Byrd","year":"2021","unstructured":"Byrd, J. C., Cortes, J. E., Minden, M. D., Oellerich, T., Stein, E. M., Elder, J., Kumar, P., Bray, G., DiMartino, J., & Stock, W. (2021). A phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of entospletinib in combination with intensive induction and consolidation chemotherapy in adults with newly diagnosed N ucleophosmin 1- mutated acute myeloid leukemia. Blood, 138(1), 1282\u20131282. https:\/\/doi.org\/10.1182\/blood-2021-145773","journal-title":"Blood"},{"issue":"1","key":"2421_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1124\/jpet.123.001752","volume":"388","author":"Y Cai","year":"2024","unstructured":"Cai, Y., He, J., Wu, Z., He, W., Dai, X., Xu, Y., Cheng, M., Yang, N., Ren, Y., Wang, G., Wang, J., Sai, Y., Jia, H., Dai, G., Li, X., & Su, W. (2024). Preclinical pharmacology characterization of sovleplenib (HMPL-523), an orally available Syk inhibitor. The Journal of Pharmacology and Experimental Therapeutics, 388(1), 156\u2013170. https:\/\/doi.org\/10.1124\/jpet.123.001752","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"2421_CR8","doi-asserted-by":"publisher","first-page":"5932","DOI":"10.1182\/blood-2022-159087","volume":"140","author":"LA Carvajal","year":"2022","unstructured":"Carvajal, L. A., McKeown, M., Hood, T., Kumar, P., Saffran, D. C., & DiMartino, J. (2022). SYK inhibitors, entospletinib and lanraplenib, show potent anti-leukemic activity in combination with targeted agents. Blood, 140(1), 5932\u20135933. https:\/\/doi.org\/10.1182\/blood-2022-159087","journal-title":"Blood"},{"issue":"2","key":"2421_CR9","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2159-8290.CD-19-0209","volume":"10","author":"A Cremer","year":"2020","unstructured":"Cremer, A., Ellegast, J. M., Alexe, G., Frank, E. S., Ross, L., Chu, S. H., Pikman, Y., Robichaud, A., Goodale, A., H\u00e4upl, B., Mohr, S., Rao, A. V., Walker, A. R., Blachly, J. S., Piccioni, F., Armstrong, S. A., Byrd, J. C., Oellerich, T., & Stegmaier, K. (2020). Resistance mechanisms to SYK inhibition in acute myeloid leukemia. Cancer Discovery, 10(2), 214\u2013231. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0209","journal-title":"Cancer Discovery"},{"issue":"3","key":"2421_CR10","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1124\/pharmrev.121.000408","volume":"74","author":"M Dambrova","year":"2022","unstructured":"Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., Smesny, S., Sen, Z. D., Guo, A. C., Oler, E., Tian, S., Zheng, J., Wishart, D. S., Liepinsh, E., & Schi\u00f6th, H. B. (2022). Acylcarnitines: Nomenclature, biomarkers, therapeutic potential, drug targets, and clinical trials. Pharmacological Reviews, 74(3), 506\u2013551. https:\/\/doi.org\/10.1124\/pharmrev.121.000408","journal-title":"Pharmacological Reviews"},{"issue":"Supplement 1","key":"2421_CR11","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1182\/blood-2021-150014","volume":"138","author":"N Daver","year":"2021","unstructured":"Daver, N., Lee, K. H., Jung, C. W., Yoon, S.-S., Arellano, M. L., Yoon, J., Lee, N., Kim, H., Lee, J., Jonas, B. A., & Baek, S. (2021). First in human (FIH) FLT3 and SYK inhibitor HM43239 shows single agent activity in patients (pts) with relapsed or refractory (R\/R) FLT3 mutated and wild-type acute myeloid leukemia (AML). Blood, 138(Supplement 1), 702\u2013702. https:\/\/doi.org\/10.1182\/blood-2021-150014","journal-title":"Blood"},{"issue":"10393","key":"2421_CR12","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","volume":"401","author":"CD DiNardo","year":"2023","unstructured":"DiNardo, C. D., Erba, H. P., Freeman, S. D., & Wei, A. H. (2023). Acute myeloid leukaemia. The Lancet, 401(10393), 2073\u20132086. https:\/\/doi.org\/10.1016\/S0140-6736(23)00108-3","journal-title":"The Lancet"},{"issue":"15","key":"2421_CR13","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1002\/cncr.34780","volume":"129","author":"VH Duong","year":"2023","unstructured":"Duong, V. H., Ruppert, A. S., Mims, A. S., Borate, U., Stein, E. M., Baer, M. R., Stock, W., Kovacsovics, T., Blum, W., Arellano, M. L., Schiller, G. J., Olin, R. L., Foran, J. M., Litzow, M. R., Lin, T. L., Patel, P. A., Foster, M. C., Redner, R. L., Al-Mansour, Z., \u2026 Boyiadzis, M. M. (2023). Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial. Cancer, 129(15), 2308\u20132320. https:\/\/doi.org\/10.1002\/cncr.34780","journal-title":"Cancer"},{"issue":"12","key":"2421_CR14","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00726-021-03060-1","volume":"53","author":"P Geng","year":"2021","unstructured":"Geng, P., Qin, W., & Xu, G. (2021). Proline metabolism in cancer. Amino Acids, 53(12), 1769\u20131777. https:\/\/doi.org\/10.1007\/s00726-021-03060-1","journal-title":"Amino Acids"},{"issue":"6","key":"2421_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103486","volume":"9","author":"MA Gouda","year":"2024","unstructured":"Gouda, M. A., Shunyakova, J., Naing, A., Dumbrava, E., Hong, D. S., Yuan, Y., Yang, P., Myers, A., Liang, Y., Peng, J., Karp, D., Tsimberidou, A. M., Rodon, J., Yap, T. A., Piha-Paul, S. A., Meric-Bernstam, F., & Fu, S. (2024). A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors. ESMO Open, 9(6), Article 103486. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103486","journal-title":"ESMO Open"},{"issue":"1","key":"2421_CR16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1080\/13880209.2022.2044862","volume":"60","author":"R Gu","year":"2022","unstructured":"Gu, R., Zhang, W., & Xu, D. (2022). Stachydrine is effective and selective against blast phase chronic myeloid leukaemia through inhibition of multiple receptor tyrosine kinases. Pharmaceutical Biology, 60(1), 700\u2013707. https:\/\/doi.org\/10.1080\/13880209.2022.2044862","journal-title":"Pharmaceutical Biology"},{"issue":"4","key":"2421_CR17","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ccr.2009.08.018","volume":"16","author":"CK Hahn","year":"2009","unstructured":"Hahn, C. K., Berchuck, J. E., Ross, K. N., Kakoza, R. M., Clauser, K., Schinzel, A. C., Ross, L., Galinsky, I., Davis, T. N., Silver, S. J., Root, D. E., Stone, R. M., DeAngelo, D. J., Carroll, M., Hahn, W. C., Carr, S. A., Golub, T. R., Kung, A. L., & Stegmaier, K. (2009). Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell, 16(4), 281\u2013294. https:\/\/doi.org\/10.1016\/j.ccr.2009.08.018","journal-title":"Cancer Cell"},{"issue":"7","key":"2421_CR18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrm.2016.25","volume":"17","author":"CH Johnson","year":"2016","unstructured":"Johnson, C. H., Ivanisevic, J., & Siuzdak, G. (2016). Metabolomics: Beyond biomarkers and towards mechanisms. Nature Reviews Molecular Cell Biology, 17(7), 451\u2013459. https:\/\/doi.org\/10.1038\/nrm.2016.25","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"10","key":"2421_CR19","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.tips.2024.08.006","volume":"45","author":"S Joshi","year":"2024","unstructured":"Joshi, S. (2024). New insights into SYK targeting in solid tumors. Trends in Pharmacological Sciences, 45(10), 904\u2013918. https:\/\/doi.org\/10.1016\/j.tips.2024.08.006","journal-title":"Trends in Pharmacological Sciences"},{"issue":"2","key":"2421_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00425-3","volume":"11","author":"H Kantarjian","year":"2021","unstructured":"Kantarjian, H., Kadia, T., DiNardo, C., Daver, N., Borthakur, G., Jabbour, E., Garcia-Manero, G., Konopleva, M., & Ravandi, F. (2021). Acute myeloid leukemia: Current progress and future directions. Blood Cancer Journal, 11(2), Article 41. https:\/\/doi.org\/10.1038\/s41408-021-00425-3","journal-title":"Blood Cancer Journal"},{"issue":"22","key":"2421_CR21","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1182\/blood.V128.22.2834.2834","volume":"128","author":"JB Kaplan","year":"2016","unstructured":"Kaplan, J. B., Bixby, D. L., Morris, J. C., Frankfurt, O., Altman, J., Wise-Draper, T., Burke, P. W., Collins, S., Kannan, K., Wang, L., Faucette, S., Lee, B., Shou, Y., Levis, M. J., & Pratz, K. W. (2016). A phase 1b\/2 study of TAK-659, an investigational dual SYK and FLT-3 inhibitor, in patients (Pts) with relapsed or refractory acute myelogenous leukemia (R\/R AML). Blood, 128(22), 2834\u20132834. https:\/\/doi.org\/10.1182\/blood.V128.22.2834.2834","journal-title":"Blood"},{"issue":"2","key":"2421_CR22","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00018-015-2070-4","volume":"73","author":"Z Li","year":"2016","unstructured":"Li, Z., & Zhang, H. (2016). Reprogramming of glucose, fatty acid and amino acid metabolism for cancer progression. Cellular and Molecular Life Sciences\u202f: CMLS, 73(2), 377\u2013392. https:\/\/doi.org\/10.1007\/s00018-015-2070-4","journal-title":"Cellular and Molecular Life Sciences : CMLS"},{"issue":"1","key":"2421_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02141-x","volume":"10","author":"H Liu","year":"2025","unstructured":"Liu, H., Wang, S., Wang, J., Guo, X., Song, Y., Fu, K., Gao, Z., Liu, D., He, W., & Yang, L.-L. (2025). Energy metabolism in health and diseases. Signal Transduction and Targeted Therapy, 10(1), Article 69. https:\/\/doi.org\/10.1038\/s41392-025-02141-x","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"2421_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100675","volume":"44","author":"JE Meg\u00edas-Vericat","year":"2020","unstructured":"Meg\u00edas-Vericat, J. E., Ballesta-L\u00f3pez, O., Barrag\u00e1n, E., Mart\u00ednez-Cuadr\u00f3n, D., & Montesinos, P. (2020). Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control? Blood Reviews, 44, Article 100675. https:\/\/doi.org\/10.1016\/j.blre.2020.100675","journal-title":"Blood Reviews"},{"issue":"10","key":"2421_CR25","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1182\/blood.2022018092","volume":"141","author":"SK Mishra","year":"2023","unstructured":"Mishra, S. K., Millman, S. E., & Zhang, L. (2023). Metabolism in acute myeloid leukemia: Mechanistic insights and therapeutic targets. Blood, 141(10), 1119\u20131135. https:\/\/doi.org\/10.1182\/blood.2022018092","journal-title":"Blood"},{"issue":"6","key":"2421_CR26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/nri2765","volume":"10","author":"A M\u00f3csai","year":"2010","unstructured":"M\u00f3csai, A., Ruland, J., & Tybulewicz, V. L. J. (2010). The SYK tyrosine kinase: A crucial player in diverse biological functions. Nature Reviews Immunology, 10(6), 387\u2013402. https:\/\/doi.org\/10.1038\/nri2765","journal-title":"Nature Reviews Immunology"},{"issue":"2","key":"2421_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/biom13020223","volume":"13","author":"KA Mosevoll","year":"2023","unstructured":"Mosevoll, K. A., Hansen, B. A., Gundersen, I. M., Reikvam, H., Bruserud, \u00d8., Bruserud, \u00d8., & Wendelbo, \u00d8. (2023). Systemic metabolomic profiles in adult patients with bacterial sepsis: Characterization of patient heterogeneity at the time of diagnosis. Biomolecules, 13(2), Article 223. https:\/\/doi.org\/10.3390\/biom13020223","journal-title":"Biomolecules"},{"issue":"11","key":"2421_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-03156-8","volume":"11","author":"A Polak","year":"2020","unstructured":"Polak, A., Bialopiotrowicz, E., Krzymieniewska, B., Wozniak, J., Stojak, M., Cybulska, M., Kaniuga, E., Mikula, M., Jablonska, E., Gorniak, P., Noyszewska-Kania, M., Szydlowski, M., Piechna, K., Piwocka, K., Bugajski, L., Lech-Maranda, E., Barankiewicz, J., Kolkowska-Lesniak, A., Patkowska, E., \u2026 Juszczynski, P. (2020). SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism. Cell Death & Disease, 11(11), Article 956. https:\/\/doi.org\/10.1038\/s41419-020-03156-8","journal-title":"Cell Death & Disease"},{"issue":"3","key":"2421_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3324\/haematol.2022.281216","volume":"108","author":"KW Pratz","year":"2022","unstructured":"Pratz, K. W., Kaplan, J., Levy, M., Bixby, D., Burke, P. W., Erba, H., Wise-Draper, T. M., Roboz, G. J., Papadantonakis, N., Rajkhowa, T., Hernandez, D., Dobler, I., Gregory, R. C., Li, C., Wang, S., Stumpo, K., Kannan, K., Miao, H., & Levis, M. (2022). A phase Ib trial of mivavotinib (TAK-659), a dual SYK\/FLT3 inhibitor, in patients with relapsed\/refractory acute myeloid leukemia. Haematologica, 108(3), 705\u2013716. https:\/\/doi.org\/10.3324\/haematol.2022.281216","journal-title":"Haematologica"},{"issue":"2","key":"2421_CR30","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ccr.2014.01.022","volume":"25","author":"A Puissant","year":"2014","unstructured":"Puissant, A., Fenouille, N., Alexe, G., Pikman, Y., Bassil, C. F., Mehta, S., Du, J., Kazi, J. U., Luciano, F., R\u00f6nnstrand, L., Kung, A. L., Aster, J. C., Galinsky, I., Stone, R. M., DeAngelo, D. J., Hemann, M. T., & Stegmaier, K. (2014). SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell, 25(2), 226\u2013242. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.022","journal-title":"Cancer Cell"},{"issue":"7","key":"2421_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/metabo13070855","volume":"13","author":"P Sen","year":"2023","unstructured":"Sen, P., & Ore\u0161i\u010d, M. (2023). Integrating omics data in genome-scale metabolic modeling: A methodological perspective for precision medicine. Metabolites, 13(7), Article 855. https:\/\/doi.org\/10.3390\/metabo13070855","journal-title":"Metabolites"},{"issue":"3","key":"2421_CR32","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony, S., Stahl, M., & Stone, R. M. (2023). Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. American Journal of Hematology, 98(3), 502\u2013526. https:\/\/doi.org\/10.1002\/ajh.26822","journal-title":"American Journal of Hematology"},{"issue":"2","key":"2421_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.3324\/haematol.2022.280800","volume":"108","author":"P Stelmach","year":"2023","unstructured":"Stelmach, P., & Trumpp, A. (2023). Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica, 108(2), 353\u2013366. https:\/\/doi.org\/10.3324\/haematol.2022.280800","journal-title":"Haematologica"},{"key":"2421_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678008","volume":"11","author":"B Stockard","year":"2021","unstructured":"Stockard, B., Bhise, N., Shin, M., Guingab-Cagmat, J., Garrett, T. J., Pounds, S., & Lamba, J. K. (2021). Cellular metabolomics profiles associated with drug chemosensitivity in AML. Frontiers in Oncology, 11, Article 678008. https:\/\/doi.org\/10.3389\/fonc.2021.678008","journal-title":"Frontiers in Oncology"},{"issue":"51","key":"2421_CR35","doi-asserted-by":"publisher","first-page":"88697","DOI":"10.18632\/oncotarget.20733","volume":"8","author":"G Tan","year":"2017","unstructured":"Tan, G., Zhao, B., Li, Y., Liu, X., Zou, Z., Wan, J., Yao, Y., Xiong, H., & Wang, Y. (2017). Pharmacometabolomics identifies dodecanamide and leukotriene B4 dimethylamide as a predictor of chemosensitivity for patients with acute myeloid leukemia treated with cytarabine and anthracycline. Oncotarget, 8(51), 88697\u201388707. https:\/\/doi.org\/10.18632\/oncotarget.20733","journal-title":"Oncotarget"},{"issue":"1","key":"2421_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-96660-w","volume":"15","author":"S Tausch","year":"2025","unstructured":"Tausch, S., Villinger, C., Alexe, G., Urban, D. J., Shen, M., Jahn, D., Vischedyk, J., Scheich, S., Serve, H., Hall, M. D., Stegmaier, K., Oellerich, T., & Cremer, A. (2025). Inflammatory signaling pathways play a role in SYK inhibitor resistant AML. Scientific Reports, 15(1), Article 11673. https:\/\/doi.org\/10.1038\/s41598-025-96660-w","journal-title":"Scientific Reports"},{"issue":"22","key":"2421_CR37","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-20-1064","volume":"26","author":"AR Walker","year":"2020","unstructured":"Walker, A. R., Byrd, J. C., Blachly, J. S., Bhatnagar, B., Mims, A. S., Orwick, S., Lin, T. L., Crosswell, H. E., Zhang, D., Minden, M. D., Munugalavadla, V., Long, L., Liu, J., Pan, Y., Oellerich, T., Serve, H., Rao, A. V., & Blum, W. G. (2020). Entospletinib in combination with induction chemotherapy in previously untreated acute myeloid leukemia: Response and predictive significance of HOXA9 and MEIS1 expression. Clinical Cancer Research, 26(22), 5852\u20135859. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1064","journal-title":"Clinical Cancer Research"},{"issue":"1","key":"2421_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104257","volume":"30","author":"S Zhang","year":"2025","unstructured":"Zhang, S., Wang, L., Lu, Y., Guo, C., Zhang, T., & Zhang, L. (2025). Targeting spleen tyrosine kinase (SYK): Structure, mechanisms and drug discovery. Drug Discovery Today, 30(1), Article 104257. https:\/\/doi.org\/10.1016\/j.drudis.2024.104257","journal-title":"Drug Discovery Today"}],"container-title":["Metabolomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-026-02421-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11306-026-02421-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11306-026-02421-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:17:53Z","timestamp":1783437473000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11306-026-02421-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":38,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["2421"],"URL":"https:\/\/doi.org\/10.1007\/s11306-026-02421-9","relation":{},"ISSN":["1573-3890"],"issn-type":[{"value":"1573-3890","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"27 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"51"}}